Biologics in Paediatric Crohn's Disease
Crohn's disease affects increasing numbers of children worldwide. Generally, childhood-onset disease runs a more severe course than in adults and has a greater impact on quality of life. Therapy in children must take account of a different set of risks for toxicity compared to adults, but also...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2011-01-01
|
| Series: | Gastroenterology Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2011/287574 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832567652620435456 |
|---|---|
| author | Oliver Gouldthorpe Anthony G. Catto-Smith George Alex |
| author_facet | Oliver Gouldthorpe Anthony G. Catto-Smith George Alex |
| author_sort | Oliver Gouldthorpe |
| collection | DOAJ |
| description | Crohn's disease affects increasing numbers of children worldwide. Generally, childhood-onset disease runs a more severe course than in adults and has a greater impact on quality of life. Therapy in children must take account of a different set of risks for toxicity compared to adults, but also to their longevity. Biologic drugs present remarkable advantages in terms of disease control for children, especially in those whose disease cannot be controlled with conventional therapies, but their long-term risks are still being assessed. Data regarding biologic use in children is limited and mostly amounts to case series, but results have been promising, both in terms of controlling disease activity and improving growth parameters. Adverse reactions are infrequent in the short term, but loss of response is a long-term problem, particularly in children. More information is needed about very long term risks. Infliximab and adalimumab are the most studied agents in children, while there is relatively limited data on certolizumab and natalizumab. Further collection of data on these agents is still needed, but this should not restrict access to these agents for children in whom no other agent is effective. |
| format | Article |
| id | doaj-art-6208d4cae2b64964b44aa59b690065f5 |
| institution | Kabale University |
| issn | 1687-6121 1687-630X |
| language | English |
| publishDate | 2011-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Gastroenterology Research and Practice |
| spelling | doaj-art-6208d4cae2b64964b44aa59b690065f52025-02-03T01:00:55ZengWileyGastroenterology Research and Practice1687-61211687-630X2011-01-01201110.1155/2011/287574287574Biologics in Paediatric Crohn's DiseaseOliver Gouldthorpe0Anthony G. Catto-Smith1George Alex2Department of Paediatrics, Monash University, Clayton, VIC 3800, AustraliaDepartment of Gastroenterology and Clinical Nutrition, Royal Children's Hospital, Parkville Melbourne, VIC 3052, AustraliaDepartment of Gastroenterology and Clinical Nutrition, Royal Children's Hospital, Parkville Melbourne, VIC 3052, AustraliaCrohn's disease affects increasing numbers of children worldwide. Generally, childhood-onset disease runs a more severe course than in adults and has a greater impact on quality of life. Therapy in children must take account of a different set of risks for toxicity compared to adults, but also to their longevity. Biologic drugs present remarkable advantages in terms of disease control for children, especially in those whose disease cannot be controlled with conventional therapies, but their long-term risks are still being assessed. Data regarding biologic use in children is limited and mostly amounts to case series, but results have been promising, both in terms of controlling disease activity and improving growth parameters. Adverse reactions are infrequent in the short term, but loss of response is a long-term problem, particularly in children. More information is needed about very long term risks. Infliximab and adalimumab are the most studied agents in children, while there is relatively limited data on certolizumab and natalizumab. Further collection of data on these agents is still needed, but this should not restrict access to these agents for children in whom no other agent is effective.http://dx.doi.org/10.1155/2011/287574 |
| spellingShingle | Oliver Gouldthorpe Anthony G. Catto-Smith George Alex Biologics in Paediatric Crohn's Disease Gastroenterology Research and Practice |
| title | Biologics in Paediatric Crohn's Disease |
| title_full | Biologics in Paediatric Crohn's Disease |
| title_fullStr | Biologics in Paediatric Crohn's Disease |
| title_full_unstemmed | Biologics in Paediatric Crohn's Disease |
| title_short | Biologics in Paediatric Crohn's Disease |
| title_sort | biologics in paediatric crohn s disease |
| url | http://dx.doi.org/10.1155/2011/287574 |
| work_keys_str_mv | AT olivergouldthorpe biologicsinpaediatriccrohnsdisease AT anthonygcattosmith biologicsinpaediatriccrohnsdisease AT georgealex biologicsinpaediatriccrohnsdisease |